Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Am J Hematol. 2012 Jun 20;87(10):953–956. doi: 10.1002/ajh.23280

Table IV.

Response and Duration

N (%) Time to Response
Median (range)
Complete Response (ALL) 1 (6%) 53 days
Partial Response (AML) 1 (6%) 77 days
Stable Disease (NHL, AML) 2 (12%) 68.5 days (52–85 days)
Disease Progression
No response 7 (41%)
Unevaluable* 2 (12%)
4 (24%)
*

Defined as not receiving all 12 doses of drug

HHS Vulnerability Disclosure